3-methyl-7-(3-phenylpropyl)-8-piperazin-1-yl-4,5-dihydropurine-2,6-dione

ID: ALA4527194

PubChem CID: 78213209

Max Phase: Preclinical

Molecular Formula: C19H26N6O2

Molecular Weight: 370.46

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1C(=O)NC(=O)C2C1N=C(N1CCNCC1)N2CCCc1ccccc1

Standard InChI:  InChI=1S/C19H26N6O2/c1-23-16-15(17(26)22-19(23)27)25(11-5-8-14-6-3-2-4-7-14)18(21-16)24-12-9-20-10-13-24/h2-4,6-7,15-16,20H,5,8-13H2,1H3,(H,22,26,27)

Standard InChI Key:  NAGQSFHQAMVTCR-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
    3.1986  -18.7459    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1986  -19.5672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9080  -19.9717    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9080  -18.3290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6174  -18.7459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6219  -19.5682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4056  -19.8168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8829  -19.1480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3983  -18.4847    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6465  -17.7020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4490  -17.5277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6972  -16.7449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4998  -16.5706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0497  -17.1791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8515  -17.0012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1004  -16.2178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5413  -15.6122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7415  -15.7891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7042  -19.1435    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1209  -19.8530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1130  -18.4294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9343  -18.4248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3468  -19.1344    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.9422  -19.8485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9065  -20.7930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4874  -19.9768    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9080  -17.5077    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  4  1  0
  2  3  1  0
  3  6  1  0
  5  4  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9  5  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
  8 19  1  0
 19 20  1  0
 19 21  1  0
 21 22  1  0
 20 24  1  0
 22 23  1  0
 23 24  1  0
  3 25  1  0
  2 26  2  0
  4 27  2  0
M  END

Associated Targets(Human)

GSK3A Tclin Glycogen synthase kinase-3 alpha (3764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 370.46Molecular Weight (Monoisotopic): 370.2117AlogP: 0.07#Rotatable Bonds: 4
Polar Surface Area: 80.28Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 10.31CX Basic pKa: 8.89CX LogP: 0.73CX LogD: -1.29
Aromatic Rings: 1Heavy Atoms: 27QED Weighted: 0.78Np Likeness Score: -0.37

References

1. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.,  171  [PMID:30925338] [10.1016/j.ejmech.2019.03.039]

Source